AstraZeneca (AZN) started a collaboration with Nucs AI to develop artificial intelligence-driven response prediction models for an oncology treatment, Nucs AI said Friday.
The collaboration will focus on creating predictive tools for a prostate-specific membrane antigen-targeted radioconjugate used in metastatic prostate cancer cases, the company said.
The company will modify and verify an imaging biomarker product to match upcoming radioconjugate therapies, Nucs AI said.
Price: $185.24, Change: $-0.09, Percent Change: -0.05%